Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...

Related Keywords

Poland ,Italy ,Houston ,Texas ,United States ,Italian ,Jenene Thomas ,Gill Shephard ,Walter Klemp ,Liposomal Annamycin ,Italian National Institute Of Health ,Moleculin Biotech Inc ,Linkedin ,Twitter ,Drug Administration ,Nasdaq ,Exchange Commission ,Securities Exchange ,Facebook ,Prnewswire Moleculin Biotech Inc ,Italian Medicines Agency ,Agenzia Italiana Del Farmaco ,Istituto Superiore ,Italian National Institute ,Fast Track Status ,Orphan Drug Designation ,Moleculin Biotech ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,High Efficacy ,Nc ,